𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer

✍ Scribed by E. Esteban; A.J. Lacave; J.L. Fernández; N. Corral; J.M. Buesa; E. Estrada; I. Palacio; J.M. Vieitez; I. Muñiz; E. Alvarez

Book ID
110234869
Publisher
Springer US
Year
1999
Tongue
English
Weight
68 KB
Volume
58
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized multicenter trial of cyclop
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer
✍ John M. Bennett; Patrick Byrne; Ajit Desai; Charles White; Ronald DeConti; Charl 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 388 KB

As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were post-

Phase I trial of adjuvant chemotherapy w
Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer
✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w